All In Biotech

Drug Trial Radar · NCT03587805

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials

Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,672

Actual

Start

Mar 18, 2018

Primary completion

Jul 3, 2024

Study completion Jul 3, 2024

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jul 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.

Conditions

  • Atopic Dermatitis

Interventions

  • TralokinumabDrug

    Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268)Time frame: From Week 0 up to Week 268

Locations

309 sites in 11 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Birmingham, Alabama

  • LEO Pharma Investigational Site

    Birmingham, Alabama

  • LEO Pharma Investigational Site

    Mobile, Alabama

  • LEO Pharma Investigational Site

    Fort Smith, Arkansas

  • LEO Pharma Investigational Site

    Bakersfield, California

  • LEO Pharma Investigational Site

    Beverly Hills, California

  • LEO Pharma Investigational Site

    Encinitas, California

  • LEO Pharma Investigational Site

    Fountain Valley, California

  • LEO Pharma Investigational Site

    Fremont, California

  • LEO Pharma Investigational Site

    Fullerton, California

  • LEO Pharma Investigational Site

    Los Angeles, California

  • LEO Pharma Investigational Site

    Los Angeles, California

  • LEO Pharma Investigational Site

    Los Angeles, California

  • LEO Pharma Investigational Site

    Newport Beach, California

  • LEO Pharma Investigational Site

    Northridge, California

  • LEO Pharma Investigational Site

    Palo Alto, California

  • LEO Pharma Investigational Site

    San Diego, California

  • LEO Pharma Investigational Site

    San Diego, California

  • LEO Pharma Investigational Site

    San Francisco, California

  • LEO Pharma Investigational Site

    San Luis Obispo, California

  • LEO Pharma Investigational Site

    Santa Ana, California

  • LEO Pharma Investigational Site

    Santa Monica, California

  • LEO Pharma Investigational Site

    New Haven, Connecticut

  • LEO Pharma Investigational Site

    Clearwater, Florida

  • LEO Pharma Investigational Site

    Doral, Florida

  • LEO Pharma Investigational Site

    Hialeah, Florida

  • LEO Pharma Investigational Site

    Miami, Florida

  • LEO Pharma Investigational Site 1

    Miami, Florida

  • LEO Pharma Investigational Site 2

    Miami, Florida

  • LEO Pharma Investigational Site

    North Miami Beach, Florida

  • LEO Pharma Investigational Site

    Orange Park, Florida

  • LEO Pharma Investigational Site

    Sweetwater, Florida

  • LEO Pharma Investigational Site

    Tampa, Florida

  • LEO Pharma Investigational Site

    West Palm Beach, Florida

  • LEO Pharma Investigational Site

    West Palm Beach, Florida

  • LEO Pharma Investigational Site

    Albany, Georgia

  • LEO Pharma Investigational Site

    Columbus, Georgia

  • LEO Pharma Investigational Site

    Macon, Georgia

  • LEO Pharma Investigational Site

    Newnan, Georgia

  • LEO Pharma Investigational Site

    Savannah, Georgia

Showing 40 of 309 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.